Decreased Effective Blood Volume in Edematous Disorders: What Does This Mean?

Robert W. Schrier
University of Colorado School of Medicine, Denver, Colorado

ABSTRACT
Edematous patients with renal sodium and water retention, particularly cardiac failure and cirrhosis, have been suggested to have a decreased “effective blood volume.” This enigmatic and undefined term was coined because edematous patients were found to have increased, rather than the earlier proposed decreased, blood volumes. This article discusses the advances that have occurred in understanding the pathophysiology of edema as occurs in conditions such as cardiac failure, cirrhosis, and pregnancy. The regulatory mechanisms that lead to increased sodium and water retention by the normal kidney are related to arterial underfilling, as a result of a decrease in cardiac output, arterial vasodilation, or both.


Early observations in patients with cardiac failure demonstrated renal sodium and water retention that resulted in an increase in extracellular fluid volume (ECFV) and edema. This degree of sodium and water retention in normal individuals would lead to an increase in renal sodium and water excretion, yet the reverse occurs in patients with heart failure. A similar sequence of events occurs in patients with cirrhosis. In these edematous disorders, the kidney per se, however, was not found to be directly responsible for the edema formation. Specifically, the kidneys from patients with end-stage liver disease no longer retained sodium and water when transplanted into patients with normal liver function but with ESRD.1 Moreover, renal sodium and water retention is reversed after liver transplantation in patients with cirrhosis. Heart transplantation has also been shown to reverse renal sodium and water retention in patients with cardiac failure.2 Given the evidence that the kidney can normally regulate sodium and water excretion, if heart failure or cirrhosis is reversed, the afferent signal for renal sodium and water retention in heart failure and cirrhosis was sought. Because these patients exhibit edema secondary to increased ECFV, a decrease in total ECFV or interstitial volume could not be the signal for the normal kidney to retain sodium and water.3,4

The focus then turned to a decrease in total blood volume as the potential signal for sodium and water retention in heart failure and cirrhosis. This explanation was plausible, because a decrease in blood volume (e.g., gastrointestinal hemorrhage, diarrhea) was known to be associated with renal sodium and water retention. In earlier years, this possibility actually led to volume expansion as a treatment for the edematous patient with heart failure or cirrhosis. Surprising, however, when accurate measurements became available to assess total blood volume in patients with heart failure or cirrhosis, a decrease in blood volume was not found. In fact, blood volume was frequently increased in patients with heart failure and cirrhosis. The afferent signal for renal sodium and water retention in edematous disorders continued to be perplexing. A term, therefore, emerged and became ensconced in the clinical vocabulary; specifically, sodium and water retention in edematous disorders was proposed to be due to a decrease in “effective blood volume” rather than total blood volume.5

For many years, however, this enigmatic term, which was used to explain sodium and water retention in patients with heart failure or cirrhosis, was never defined.

Cardiac output was initially proposed by Borst et al.6 as the mediator of the “effective blood volume.” This possibility was attractive, because a diminished cardiac output was a frequent finding in edematous patients with cardiac failure. However, if the normal kidney is uniformly responding to a decrease in cardiac output in edematous disorders, then a problem arises because sodium and water retention occurs in patients with cirrhosis, high-output cardiac failure, and normal pregnancy in the presence of an increase in cardiac output.

On this background, a unifying hypothesis for renal sodium and water retention that addressed most of these dilemmas was proposed.3,4,7,8 Estimates

Published online ahead of print. Publication date available at www.jasn.org.

Correspondence: Dr Robert W. Schrier, University of Colorado School of Medicine, 4200 E. Ninth Ave., B173, Denver, CO 80262. Phone: 303-315-8059; Fax: 303-315-2685; E-mail: robert.schrier@uchsc.edu

Copyright © 2007 by the American Society of Nephrology
of blood volume distribution indicate that 85% of blood circulates on the low-pressure, venous side of the circulation, whereas an estimated 15% of blood is circulating in the high-pressure, arterial circulation. Thus, an increase in total blood volume could occur, even as there is an underfilling of the arterial circulation, if the increase in total blood volume is primarily due to expansion of the venous compartment. Underfilling of the arterial circulation could occur secondary either to a decrease in cardiac output, as occurs in low-output cardiac failure, or to systemic arterial vasodilation, which occurs early in cirrhosis as a result of diminished vascular resistance in the splanchnic circulation.9,10 With this hypothesis, the events that are triggered by arterial underfilling, as a result of either a decrease in cardiac output (Figure 1A) or systemic arterial vasodilation (Figure 1B), are compensatory responses to restore arterial circulatory integrity. Because adequate arterial perfusion of vital organs is mandatory for survival, a mechanism for body fluid volume regulation by the kidney that focuses on the absolute (cardiac output) or relative (arterial vasodilation) fullness of the arterial circulation is attractive from a teleologic point of view.

In sodium- and water-retaining disorders that occur secondary to systemic arterial vasodilation, the compensatory hemodynamic response is an increase in cardiac output that occurs secondary to the reduced cardiac afterload. In both circumstances of arterial underfilling in edematous disorders, whether as a result of a decrease in cardiac output or arterial vasodilation, the neurohumoral axis is stimulated and renal sodium and water retention occurs as a compensatory mechanism to maintain arterial perfusion. This includes activation of the sympathetic system and the renin-angiotensin-aldosterone system (RAAS) as well as nonosmotic vasopressin release (Figure 1). Reversal of sodium retention with mineralocorticoid antagonist has been shown in cardiac failure11 and cirrhosis.12 Similarly, oral active, nonpeptide vasopressin V2 receptor antagonists have been shown to correct hyponatremia in cardiac failure and cirrhosis.13 In some circumstances, a decrease in both cardiac output and arterial vasodilation may be involved in arterial underfilling. Such is the case when primary arterial vasodilation occurs in cirrhosis or sepsis, because an accompanying increase in circulating TNF-α decreases myocardial contractility.14

With the primacy of the integrity of the arterial circulation in renal sodium and water retention, sensitive arterial receptors that respond to arterial under-
filling must exist. In this regard, there are sensitive stretch receptors in the carotid artery, aortic arch, and the glomerular afferent arteriole that respond to a decrease in arterial pressure. Because of the importance of arterial perfusion, the compensatory responses to arterial underfilling occur rapidly. With arterial underfilling, as a result of a decrease in cardiac output, arterial vasodilation, or both, a decrease in glossopharyngeal and vagal tone from the carotid and aortic receptors leads to a rapid increase in sympathetic activity with associated activation of the RAAS and nonosmotic release of vasopressin. The resultant increase in systemic vascular resistance and renal sodium and water retention attenuates the arterial underfilling and associated diminished arterial perfusion.

There are low-pressure receptors in the cardiac atria that suppress vasopressin release, decrease renal vascular resistance, and increase sodium and water excretion in response to an increased transmural atrial pressure. In cardiac failure, however, atrial pressure rises, yet sodium and water retention occurs. This suggests that activation of the arterial stretch receptors in cardiac failure predominate over any atrial pressure receptor reflex in cardiac failure. An increase in the ventricular synthesis of brain natriuretic hormone (BNP) and thus circulatory BNP concentrations also occurs in cardiac failure and may attenuate the degree of renal sodium and water retention. BNP may decrease the edema formation in cardiac failure by both suppressing the RAAS and inhibiting tubular sodium reabsorption.

Of further interest is the renal sodium and water retention that occurs with diastolic dysfunction in the presence of normal cardiac output, as assessed by ejection fraction. Although a decrease in stroke volume and diminished arterial pressure have been shown to release the tonic inhibition from the carotid and aortic baroreceptors on the sympathetic outflow from the central nervous system, this should not be a reflex pathway for sodium and water retention in patients with diastolic dysfunction and a normal cardiac output. There are, however, ventricular receptors that may be involved with sodium and water retention in patients with diastolic dysfunction. Similar reflexes may be involved in right ventricular failure that occurs with pulmonary hypertension in association with renal sodium and water retention. This possibility, however, is in need of investigation.

Monitoring arterial underfilling in edematous patients by measuring the hormones that are associated with activation of the neurohumoral axis is obviously neither timely nor cost-effective in the clinical setting. However, in edematous patients who are on a normal sodium intake and in the absence of diuretics, a low fractional excretion of sodium indicates clinically important arterial underfilling and should initiate a search for an associated decrease in cardiac output and/or systemic arterial vasodilation, which are potentially reversible.

A unifying pathway for body fluid volume regulation by the kidney should be applicable in both health and disease. In healthy pregnancy, systemic arterial vasodilation and a decrease in BP occur in the first trimester in association with a compensatory rise in cardiac output. As expected for a state of arterial underfilling, activation of the RAAS occurs early in normal pregnancy. Renal sodium and water retention is also a feature of normal pregnancy as is expansion of total blood volume. A decrease in plasma osmolality, stimulation of thirst, and persistent nonosmotic vasopressin release are other features of normal pregnancy. In contrast to disease states such as cardiac failure and cirrhosis, pregnancy, is associated with an increase in GFR and renal blood flow. The systemic and renal arterial vasodilation in pregnancy seems to involve nitric oxide. Estrogen upregulates endothelial nitric oxide synthase in pregnancy, and inhibitors of nitric oxide synthesis normalize the systemic and renal hemodynamics in rat pregnancy.

On the background of this unifying mechanism of body fluid volume regulation by the kidney, the clinical use of the term “decreased effective blood volume” can be considered outdated and be replaced by “arterial underfilling.” However, if the use of the term persists in clinical medicine, then it should be “decreased effective arterial blood volume.”

ACKNOWLEDGMENTS

The author’s research cited in this article was supported by National Institutes of Health grant PO1 DR19928 and General Clinical Research Center grant M01 RR000051.

The assistance of Jan Darling in preparation of the manuscript is appreciated.

DISCLOSURES

None.

REFERENCES

13. Schrier RW, Gross P, Gheorghiade M, Berl T, Verbalis JG, Czerwiec FS, Orlandi C, SALT Investigators: Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hypo-
14. Carlson DL, Willis MS, White DJ, Horton JW, Giroir BP: Tumor necrosis factor-alpha-induced caspase activation mediates endo-
toxin-related cardiac dysfunction. *Crit Care Med* 33: 1021–1028, 2005
uretic peptide in patients with hemodynam-
17. De Keulenaer GW, Brutsaert DL: Systolic and diastolic heart failure: Different pheno-
19. Schrier RW, Briner VA: Peripheral arterial va-
ation and glomerular hyperfiltration in preg-